Telix Pharmaceuticals Limited
TLX
$9.36
-$0.07-0.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.88% | 69.59% | 48.80% | 52.28% | 53.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.88% | 69.59% | 48.80% | 52.28% | 53.83% |
| Cost of Revenue | 96.49% | 155.73% | 43.82% | 47.18% | 60.45% |
| Gross Profit | 32.14% | 25.07% | 52.09% | 55.64% | 49.44% |
| SG&A Expenses | 45.95% | 60.00% | 60.18% | 63.92% | 78.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 83.07% | 285.17% | 172.44% | 174.14% | 127.03% |
| Total Operating Expenses | 66.69% | 103.20% | 47.14% | 50.58% | 111.87% |
| Operating Income | -110.72% | -103.09% | 69.56% | 73.52% | -77.85% |
| Income Before Tax | -141.45% | -114.40% | 38.89% | 42.14% | 319.14% |
| Income Tax Expenses | 27.95% | -125.57% | 126.76% | 127.38% | -243.40% |
| Earnings from Continuing Operations | -115.08% | -109.70% | 3.75% | 6.17% | 295.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -115.08% | -109.70% | 3.75% | 6.17% | 295.18% |
| EBIT | -110.72% | -103.09% | 69.56% | 73.52% | -77.85% |
| EBITDA | -58.16% | -85.04% | 62.78% | 66.58% | -72.85% |
| EPS Basic | -129.57% | -109.32% | -0.51% | 2.01% | 194.26% |
| Normalized Basic EPS | -134.67% | -108.02% | 137.36% | 141.30% | -82.19% |
| EPS Diluted | -130.63% | -109.55% | -2.59% | -0.52% | 190.98% |
| Normalized Diluted EPS | -136.11% | -108.20% | 130.34% | 137.08% | -82.90% |
| Average Basic Shares Outstanding | -48.77% | 4.12% | 4.33% | 4.33% | 106.86% |
| Average Diluted Shares Outstanding | -50.73% | 1.68% | 6.54% | 6.54% | 115.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |